# Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin

> **NCT06921941** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR
- **DRUG:** Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR

## Key facts

- **NCT ID:** NCT06921941
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-08
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-07-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921941, "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06921941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*